|
METAGLIP™
(glipizide and metformin HCl Tablets)
IMPORTANT
SAFETY INFORMATION
METAGLIP™
is not for everyone. In rare cases, METAGLIP may cause lactic acidosis
(buildup of lactic acid in the blood), which is serious and can
be fatal in half the cases. This occurs mainly in people whose kidneys
are not functioning properly. Tell your physician or healthcare
professional about your alcohol use, because it can increase your
risk. You should not take METAGLIP if you: have kidney problems,
are 80 or older (unless your kidneys are tested), are taking medicine
for heart failure, are seriously dehydrated, have a severe infection,
have or have had liver disease, are allergic to glipizide or metformin
hydrochloride, or suffer from metabolic acidosis, including diabetic
ketoacidosis.
The most common
side effects of METAGLIP are diarrhea, nausea/vomiting and upset
stomach. Symptoms of hypoglycemia (low blood sugar) such as lightheadedness,
dizziness, shakiness, or hunger may also occur.
Remember to
discuss with your physician any prescription and non-prescription
drugs you are taking as well as any health problems you have before
starting METAGLIP.
INDICATIONS
AND USAGE
METAGLIP is indicated as initial therapy, as an adjunct to diet
and exercise, to improve glycemic control in patients with type
2 diabetes whose hyperglycemia cannot be satisfactorily managed
with diet or exercise alone.
METAGLIP is indicated as second-line therapy when diet, exercise
and initial therapy with a sulfonylurea or metformin do not result
in adequate glycemic control in patients with type 2 diabetes.
Available only
by prescription.
|
